Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Breast and ovarian cancer screening practices in healthy women with a strong family history of breast or ovarian cancer.

Isaacs C, Peshkin BN, Schwartz M, Demarco TA, Main D, Lerman C.

Breast Cancer Res Treat. 2002 Jan;71(2):103-12.

PMID:
11881908
2.

Factors associated with the incompliance with mammogram screening among individuals with a family history of breast cancer or ovarian cancer.

Wu H, Zhu K, Jatoi I, Shah M, Shriver CD, Potter J.

Breast Cancer Res Treat. 2007 Mar;101(3):317-24. Epub 2006 Jul 4.

PMID:
16821080
4.

Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.

MacDonald DJ, Sarna L, Uman GC, Grant M, Weitzel JN.

Oncol Nurs Forum. 2006 Nov 3;33(2):E27-35.

PMID:
16518435
5.

Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing.

Botkin JR, Smith KR, Croyle RT, Baty BJ, Wylie JE, Dutson D, Chan A, Hamann HA, Lerman C, McDonald J, Venne V, Ward JH, Lyon E.

Am J Med Genet A. 2003 Apr 30;118A(3):201-9.

PMID:
12673648
6.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
7.

Screening adherence in BRCA1/2 families is associated with primary physicians' behavior.

Tinley ST, Houfek J, Watson P, Wenzel L, Clark MB, Coughlin S, Lynch HT.

Am J Med Genet A. 2004 Feb 15;125A(1):5-11.

PMID:
14755459
8.

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.

Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.

PMID:
20204502
9.

Awareness and concern about ovarian cancer among women at risk because of a family history of breast or ovarian cancer.

Andersen MR, Bowen D, Yasui Y, McTiernan A.

Am J Obstet Gynecol. 2003 Oct;189(4 Suppl):S42-7.

PMID:
14586320
10.

BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.

McInerney-Leo A, Biesecker BB, Hadley DW, Kase RG, Giambarresi TR, Johnson E, Lerman C, Struewing JP.

Am J Med Genet A. 2004 Oct 15;130A(3):221-7.

PMID:
15378542
11.

Cancer surveillance behaviors in women presenting for clinical BRCA genetic susceptibility testing.

Loescher LJ, Lim KH, Leitner O, Ray J, D'Souza J, Armstrong CM.

Oncol Nurs Forum. 2009 Mar;36(2):E57-67. doi: 10.1188/09.ONF. E57-E67.

12.

Breast cancer and ovarian cancer genetics.

Edlich RF, Winters KL, Lin KY.

J Long Term Eff Med Implants. 2005;15(5):533-45. Review.

PMID:
16218901
13.

Mammography adherence and psychological distress among women at risk for breast cancer.

Lerman C, Daly M, Sands C, Balshem A, Lustbader E, Heggan T, Goldstein L, James J, Engstrom P.

J Natl Cancer Inst. 1993 Jul 7;85(13):1074-80.

PMID:
8515494
14.

Factors associated with decisions about clinical BRCA1/2 testing.

Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B.

Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4.

15.

Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.

Martin AM, Blackwood MA, Antin-Ozerkis D, Shih HA, Calzone K, Colligon TA, Seal S, Collins N, Stratton MR, Weber BL, Nathanson KL.

J Clin Oncol. 2001 Apr 15;19(8):2247-53.

PMID:
11304778
16.

Current policies for surveillance and management in women at risk of breast and ovarian cancer: a survey among 16 European family cancer clinics. European Familial Breast Cancer Collaborative Group.

Vasen HF, Haites NE, Evans DG, Steel CM, Møller P, Hodgson S, Eccles D, Morrison P, Stoppa Lyonet D, Chang-Claude J, Caligo M.

Eur J Cancer. 1998 Nov;34(12):1922-6.

PMID:
10023316
17.

Guidelines for genetic risk assessment of hereditary breast and ovarian cancer: early disagreements and low utilization.

Levy DE, Garber JE, Shields AE.

J Gen Intern Med. 2009 Jul;24(7):822-8. doi: 10.1007/s11606-009-1009-6. Epub 2009 May 20.

18.

Family history of breast and ovarian cancer and the risk of breast carcinoma in situ.

Claus EB, Stowe M, Carter D.

Breast Cancer Res Treat. 2003 Mar;78(1):7-15.

PMID:
12611452
19.

BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, Ganguly A, Rebbeck T, Weber BL.

N Engl J Med. 1997 May 15;336(20):1409-15.

20.

Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.

Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A.

J Natl Cancer Inst. 2001 Aug 15;93(16):1215-23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk